{"id":"NCT01617655","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C Higher or Equal to 160mg/dL With Their Lipid-Modifying Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2014-05","completion":"2015-01","firstPosted":"2012-06-12","resultsPosted":"2015-11-06","lastUpdate":"2016-10-04"},"enrollment":107,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolaemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent"]},{"type":"DRUG","name":"Placebo (for alirocumab)","otherNames":[]},{"type":"DRUG","name":"Lipid Modifying Therapy (LMT)","otherNames":[]}],"arms":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Alirocumab 150 mg Q2W","type":"EXPERIMENTAL"}],"summary":"Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).\n\nPrimary Objective of the study:\n\nTo evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points\n* To evaluate the effects of alirocumab on other lipid parameters\n* To evaluate the safety and tolerability of alirocumab","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis","timeFrame":"From Baseline to Week 52","effectByArm":[{"arm":"Placebo Q2W","deltaMin":-6.6,"sd":4.9},{"arm":"Alirocumab 150 mg Q2W","deltaMin":-45.7,"sd":3.5}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":35,"countries":["United States","Canada","Netherlands","Russia","South Africa"]},"refs":{"pmids":["24842558","27618825","34298554","30183102","28964736","28391886","27777279"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":35},"commonTop":["Nasopharyngitis","Influenza","Injection site reaction","Diarrhoea","Myalgia"]}}